Published in Nucleic Acid Ther on June 01, 2013
Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood (2016) 2.10
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med (2015) 0.98
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res (2015) 0.88
Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med (2014) 0.87
Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep (2016) 0.84
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene (2015) 0.83
Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1. J Pharmacol Exp Ther (2015) 0.82
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun (2015) 0.81
Injection site reactions after subcutaneous oligonucleotide therapy. Br J Clin Pharmacol (2016) 0.79
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers. Mol Ther (2016) 0.77
The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse. Toxicol Rep (2015) 0.77
Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. Mol Neurobiol (2016) 0.75
Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides. Sci Rep (2016) 0.75
Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice. Mol Ther Nucleic Acids (2017) 0.75
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res (2012) 5.04
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature (2007) 4.33
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest (2007) 3.88
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest (2006) 3.75
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet (2002) 3.25
Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol (2008) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem (2007) 2.55
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol (2013) 2.43
The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab (2009) 2.35
Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol (2013) 2.34
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology (2005) 2.25
Cardiomyocyte proliferation contributes to heart growth in young humans. Proc Natl Acad Sci U S A (2013) 2.16
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood (2010) 2.14
Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest (2006) 2.13
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res (2007) 1.99
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res (2006) 1.98
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest (2004) 1.93
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes (2002) 1.91
SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A (2009) 1.89
Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest (2004) 1.83
Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol (2005) 1.77
Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood (2010) 1.77
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A (2002) 1.73
Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol (2004) 1.71
Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes (2004) 1.65
Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. Mol Cell (2012) 1.61
Ketonethiosemicarbazones: structure-activity relationships for their melanogenesis inhibition. Bioorg Med Chem Lett (2011) 1.60
Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther (2002) 1.58
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos (2003) 1.57
Transient receptor potential canonical type 3 channels facilitate endothelium-derived hyperpolarization-mediated resistance artery vasodilator activity. Cardiovasc Res (2012) 1.56
Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res (2010) 1.55
Antisense therapy for cancer. Nat Rev Cancer (2005) 1.54
Induction of dendritic cell maturation by β-glucan isolated from Sparassis crispa. Int Immunopharmacol (2010) 1.53
Protective role of autophagy in palmitate-induced INS-1 beta-cell death. Endocrinology (2008) 1.52
Leucine-rich repeat containing 8A (LRRC8A) is essential for T lymphocyte development and function. J Exp Med (2014) 1.49
An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J Biol Chem (2002) 1.48
Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett (2004) 1.48
Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther (2006) 1.46
Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res (2006) 1.46
Angiomyofibroblastoma of the vagina in a breast cancer patient. Pathology (2008) 1.45
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest (2013) 1.44
Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis. J Gastroenterol Hepatol (2007) 1.42
Therapeutic potential for microRNAs. Adv Drug Deliv Rev (2007) 1.41
Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem (2004) 1.40
Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. J Clin Invest (2005) 1.35
Structural requirement(s) of N-phenylthioureas and benzaldehyde thiosemicarbazones as inhibitors of melanogenesis in melanoma B 16 cells. Bioorg Med Chem Lett (2010) 1.32
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab (2009) 1.31
Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol (2013) 1.30
JNK pathway is involved in the inhibition of inflammatory target gene expression and NF-kappaB activation by melittin. J Inflamm (Lond) (2008) 1.30
Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology (2006) 1.29
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos (2006) 1.27
Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res (2005) 1.27
Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res (2005) 1.24
Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology (2008) 1.24
Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology (2010) 1.23
Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer (2009) 1.22
Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood (2011) 1.22
Oxyresveratrol and hydroxystilbene compounds. Inhibitory effect on tyrosinase and mechanism of action. J Biol Chem (2002) 1.21
Identification of novel PPARgamma target genes in primary human adipocytes. Gene (2005) 1.20
Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res (2007) 1.18
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.18
The transcription factor GLI1 mediates TGFβ1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS One (2012) 1.17
Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid (2012) 1.16
Human mediator enhances activator-facilitated recruitment of RNA polymerase II and promoter recognition by TATA-binding protein (TBP) independently of TBP-associated factors. Mol Cell Biol (2003) 1.16
Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol (2003) 1.16
Crystal structure of PilF: functional implication in the type 4 pilus biogenesis in Pseudomonas aeruginosa. Biochem Biophys Res Commun (2005) 1.15
Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood (2012) 1.15
Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol (2006) 1.15
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol (2007) 1.14
Bcl-2 sustains increased mucous and epithelial cell numbers in metaplastic airway epithelium. Am J Respir Crit Care Med (2004) 1.14
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol (2008) 1.14
Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 1.11
Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics (2007) 1.11
The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood (2002) 1.10
SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK signaling pathway during B lymphopoiesis. Immunity (2007) 1.10
Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance. J Lipid Res (2011) 1.08
Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem (2008) 1.08
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes (2002) 1.07
O-GlcNAc modulation at Akt1 Ser473 correlates with apoptosis of murine pancreatic beta cells. Exp Cell Res (2008) 1.07
Involvement of Ca2+-mediated apoptotic signals in palmitate-induced MIN6N8a beta cell death. Mol Cell Endocrinol (2007) 1.05
PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene (2002) 1.05
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood (2014) 1.05
Drosophila melanogaster-based screening for multihost virulence factors of Pseudomonas aeruginosa PA14 and identification of a virulence-attenuating factor, HudA. Infect Immun (2008) 1.04
Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res (2004) 1.04
Fast synthesis of high-performance graphene films by hydrogen-free rapid thermal chemical vapor deposition. ACS Nano (2014) 1.02
Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res (2002) 1.02